Table 1

Characteristics of the patients of the entire study population and according to the early use of steroids

CharacteristicsTotal
(N=151)
n (%)
Control cohort
(n=116)
n (%)
Exposed cohort
(n=35)
n (%)
OR (95% CI)P value
Age (years)<6564 (42)45 (39)19 (54)0.12
≥6587 (58)71 (61)16 (46)
GenderMale89 (59)73 (63)16 (46)0.08
Female62 (41)43 (37)19 (54)
SmokingNever or former103 (71)83 (75)20 (57)0.06
Current43 (29)28 (25)15 (43)
NA550
ECOG PS0–1142 (94)112 (97)30 (86)4.57 (1.10 to 20.37) 0 .03
≥29 (6)4 (3)5 (14)
HistologySquamous33 (22)29 (25)4 (11)0.11
Non-squamous118 (78)87 (75)31 (89)
PD-L1 statusNegative46 (51)37 (51)9 (47)0.80
Positive45 (49)35 (49)10 (53)
NA604416
Metastatic sites (N)1–265 (43)57 (49)8 (23)3.20 (1.38 to 8.16) 0 .006
>286 (57)59 (51)27 (77)
Brain metsNo118 (78)99 (85)19 (54)4.83 (2.07 to 11.41) < 0.001
Yes33 (22)17 (15)16 (46)
Liver metsNo117 (77)89 (77)28 (80)0.68
Yes34 (23)27 (23)7 (20)
Bone metsNo87 (58)72 (62)15 (43)0.05
Yes64 (42)44 (38)20 (57)
Line of treatment1–285 (56)65 (56)20 (57)1
>266 (44)51 (44)15 (43)
ICI regimenMono145 (96)110 (95)35 (100)0.34
Dual6 (4)6 (5)0 (0)
  • P values below the significance threshold are reported in bold.

  • ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICI, immune checkpoint inhibitor; NA, not available.